Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study.
The Lancet. Oncology（2023）
摘要
BeiGene.
更多查看译文
关键词
squamous cell carcinoma,cell carcinoma,chemotherapy,first-line,placebo-controlled
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要